Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Can-Fite BioPharma ( (CANF) ) has issued an announcement.
On December 23, 2025, Can-Fite BioPharma announced that, following shareholder approval on November 10, 2025, its board authorized a 1-for-3,000 reverse split of the company’s ordinary shares and a concurrent change in the ratio of ordinary shares underlying its American Depositary Shares (ADSs). The reverse split, which will reduce the total number of outstanding ordinary shares and proportionally cut authorized share capital from 42 billion to 14 million, will take effect on the Tel Aviv Stock Exchange in early January 2026, with first trading in the consolidated shares set for January 5, 2026, while the ADS ratio change to one ADS representing two ordinary shares—operationally a one‑for‑twenty ADS split—will become effective on NYSE American the same day, preserving shareholders’ proportional ownership and voting power aside from minor rounding effects and aiming to support a higher per‑ADS trading price and continued market listing stability.
The most recent analyst rating on (CANF) stock is a Sell with a $0.24 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Underperform.
The overall stock score of 39 reflects significant financial challenges and bearish technical indicators. The lack of valuation metrics further underscores potential concerns about profitability and shareholder returns. Strategic improvements in financial performance and market sentiment are crucial for enhancing the stock’s outlook.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is an advanced clinical-stage biotechnology company developing proprietary small-molecule drugs targeting cancer, liver, and inflammatory diseases, with a focus on multi-billion-dollar markets. Its lead candidate Piclidenoson is in a pivotal Phase III trial for psoriasis, while Namodenoson is in Phase III for hepatocellular carcinoma, Phase IIb for MASH, and Phase IIa for pancreatic cancer, and holds Orphan Drug and Fast Track designations in key indications; a third candidate, CF602, has shown efficacy in treating erectile dysfunction, and the company reports an extensive safety database across more than 1,600 patients.
Average Trading Volume: 6,469,722
Technical Sentiment Signal: Sell
Current Market Cap: $24.55M
See more data about CANF stock on TipRanks’ Stock Analysis page.